scholarly journals Differences in Gastric Carcinoma Microenvironment Stratify According to EBV Infection Intensity: Implications for Possible Immune Adjuvant Therapy

2013 ◽  
Vol 9 (5) ◽  
pp. e1003341 ◽  
Author(s):  
Michael J. Strong ◽  
Guorong Xu ◽  
Joseph Coco ◽  
Carl Baribault ◽  
Dass S. Vinay ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Gastric Carcinoma ◽  
Infection Intensity ◽  
Ebv Infection ◽  
Immune Adjuvant

scholarly journals Common Epstein-Barr virus (EBV) type-1 variant strains in both malignant and benign EBV-associated disorders

Blood ◽  
1996 ◽  
Vol 87 (4) ◽  
pp. 1579-1585 ◽  
Author(s):  
V Schuster ◽  
G Ott ◽  
S Seidenspinner ◽  
HW Kreth
Keyword(s):  
Gastric Carcinoma ◽  
Epstein Barr Virus ◽  
Hodgkin's Lymphoma ◽  
Sequence Pattern ◽  
Barr Virus ◽  
Ebv Infection ◽  
Epstein Barr

In the present study, Epstein-Barr virus (EBV) isolates from 18 malignant tumors (angioimmunoblastic lymphadenopathy [AILD], n = 4; Hodgkin's disease [HD], n = 3; pleomorphic T-cell non-Hodgkin's lymphoma [T-NHL], n = 1; B-cell non-Hodgkin's lymphoma [B-NHL], n = 8; gastric carcinoma, n = 2) as well as from 10 tonsils of EBV- seropositive children and from peripheral blood mononuclear cells of 12 children with uncomplicated infectious mononucleosis (IM) and of a boy with severe chronic active EBV infection were genotyped in the EBV nuclear antigen-2 (EBNA-2) gene. A total of 40 of 41 isolates harbored EBV type 1; in 1 specimen (tonsil), only EBV type 2 was found. Further molecular characterization of EBV type-1 wild-type isolates in the EBNA- 2 gene and in the 40-kb distant EBV-encoded small RNAs (EBER) region showed that different groups of stable EBV type-1 variant strains exist in vivo both in benign and malignant lymphatic tissue. Group 1 is composed of EBV type-1 isolates (B-NHL, n = 3; T-NHL, n = 1; HD, n = 1; IM, n = 4) that showed a B95–8-like DNA sequence pattern in both viral genes. Group 2 isolates (HD, n = 1; AILD, n = B-NHL, n = 1; tonsils of EBV-seropositive children, n = 9; IM, n = 20 showed a nucleotide change at position 49095 in the EBNA-2 gene, leading to an amino acid substitution (Pro-->Ser), and EBV type-2 sequences in the EBER region. EBV type-1 isolates that fall into group 3 (AILD, n = 3; HD, n = 1; B- NHL, n = 4; gastric carcinoma, n = 2; IM, n = 6; severe chronic active EBV infection, n = 1) were characterized by typical nucleotide changes and a 3-bp insertion (CTC; extra Leu residue) in the EBNA-2 gene and an EBV type-2-specific sequence pattern in the EBER region. These EBV type- 1 variant strains may represent the most prevalent circulating EBV type- 1 strains in the exposed population and seem not to be restricted to a certain EBV-associated disease or tumor type. However, analysis of more EBV isolates from benign and malignant lesions must show whether more EBV type-1 substrains exist in vivo.

Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma.

1984 ◽  
Vol 2 (11) ◽  
pp. 1249-1254 ◽  
Author(s):  
C G Moertel ◽  
D S Childs ◽  
J R O'Fallon ◽  
M A Holbrook ◽  
A J Schutt ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Gastric Carcinoma ◽  
Poor Prognosis ◽  
Survival Rates ◽  
Treatment Refusal ◽  
Clinical Recurrence ◽  
Treatment Assignment ◽  
Potential Problems ◽  
Regional Component

Sixty-two patients with resectable but poor-prognosis gastric carcinoma were randomized to either no surgical adjuvant therapy or treatment with 5-fluorouracil (15 mg/kg by rapid intravenous injection X 3) plus radiation (3,750 rad in 24 fractions) initiated 3 1/2 to six weeks postoperatively. Informed consent was obtained after randomization and only from the 39 randomized to treatment. Ten patients refused their treatment assignment. The five-year survival rate for patients randomized to treatment was 23%, and for those randomized to no treatment, 4% (P less than .05). Both the survival distributions and the alive-without-recurrence distributions were significantly different for the two groups (P = .024) and favored treatment assignment. When the treatment assignment group was broken down to those patients actually receiving treatment and those refusing, five-year survival rates were: treated, 20%; treatment refusal, 30%; controls, 4%; the three survival distributions were not significantly different. Thirty-nine percent of patients actually treated had a local-regional component of first clinical recurrence compared with 54% of those who received no treatment. This study does not establish 5-fluorouracil plus radiation as effective surgical adjuvant therapy for gastric cancer but suggests this approach as a possible fruitful area for continued research. This study also illustrates the potential problems that may be encountered in interpreting results when patients are randomized to a study before consent is obtained.

Chemoimmunotherapy with 5-fluouracil, leucovorin and interferon alpha-2b as adjuvant therapy after surgery in Gastric Carcinoma patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4581-4581
Author(s):  
H. A. Gonzalez ◽  
H. Londoño ◽  
J. Quiroz ◽  
A. Parra ◽  
A. Ramirez ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Gastric Carcinoma ◽  
Interferon Alpha ◽  
Clinical Stage ◽  
Disease Free Survival ◽  
Recurrence Risk ◽  
Random Group ◽  
Interferon Alpha 2B ◽  
Group A ◽  
Group B

4581 Background: The main treatment of Gastric Carcinoma(GC) is Surgery, but 5 years recurrence risk is 70% and mortality 50%. So that, effective adyuvant therapy, like chemotherapy, is needed to impact on survival ; results, however have been inconsistent at best. Inmunotherapy with interferon alpha, in gastric carcinoma, has only been employed in metastatic disease. The objective of this study was evaluate chemoimmmunotherapy role of interferon alpha - 2b,5-FU and LCV as adjuvant therapy in GC Methods: This is a randomized prospective study. Beginning 2/Oct /97 and finalizing 31/march/2005. Patiens with gastric adenocarcinoma, clinical stages II, III and non metastatic IV, after gastrectomy, without cancer antecedent were included. Treatment groups were assigned at random: Group A: 5-FU: 400 mg/m2, days (1–3), leucovorin: 50 mg. days (1–3), interferon alpha - 2b: 5x10^6 units sq, every other day, days (1–15). Group B: 5-FU, LCV without interferon alpha, at the same doses. Nine (9) monthly cycles were aplied. Clinical and paraclinical follow up was made appropriately. Statistic analysis was performed by Kaplan Meier method. Results: 52 patients were studied, 25 in group A and 27 in group B. Both of them had similar characteristics in median age, sex, histology, differentiation grade, gastric location, clinical stage: A: II: 28%, III: 72% (IIIB: 56%). B: II: 29,6%, III: 70% (IIIB: 55%).General survival (SG) analysis: Mean SG (%): A: 64%. B: 18,5%. Mean SG (months): A: 68,5 m. (CI 95%: 59–78,15). B: 27,98 ( CI 95%: 18,92–37,04). Survival curves comparison, minimum until 5 years: Log Rank, Breslow, Tarone Ware: P<0,00001, all of them in favor to group A. Mortality: Total:31/52: 59,6%. A: 36%. B: 81,48% (P<0,05). Disease free survival (DFS) analysis: Mean DFS (%): A: 52%. B: 18, 52%. Mean DFS(months): A: 58,85m (CI 95%: 47,4–70.3). B: 24,98m (CI 95 %: 15,3–34.6). DFS curves comparison: Log Rank: 0,0008. Breslow: 0,0003. Tarone Ware: 0,0004. All of them in favor to group A. Recurrence (%): Total: 34/52:65%. A: 48%. B: 81,48% ( P <0,05). Conclusions: This is the first study of adjuvant chemoimmunotherapy (CI) that includes interferon alpha - 2b in GC. This study shows CI with 5-FU, LCV and interferon alpha -2b is effective as adjuvant treatment in GC. No significant financial relationships to disclose.

Adjuvant therapy for resected gastric carcinoma

2002 ◽  
Vol 11 (2) ◽  
pp. 431-444 ◽  
Author(s):  
Yuichi Kasakura ◽  
Alexandria Phan ◽  
Jaffer Ajani
Keyword(s):  
Adjuvant Therapy ◽  
Gastric Carcinoma

P226 EBV infection in patients with gastric carcinoma

2009 ◽  
Vol 34 ◽  
pp. S99
Author(s):  
A. Szkaradkiewicz ◽  
T. Karpinski ◽  
P. Majewski ◽  
E. Andrzejewska ◽  
B. Zwozdziak
Keyword(s):  
Gastric Carcinoma ◽  
Ebv Infection
Sign in / Sign up

Export Citation Format

Share Document